Oncology

A UK trial rules out the use of oral ketamine for the general treatment of chronic neuropathic pain in patients with cancer.

The combination of the BRAF inhibitor encorafenib and the MEK inhibitor binimetinib has favorable efficacy and tolerability relative to either encorafenib or vemurafenib alone in patients with advanced melanoma harboring BRAF mutations, phase III trial findings indicate.

Postmenopausal women who take short-acting calcium channel blockers could be at increased risk for developing pancreatic cancer, findings indicate.

Adding pembrolizumab to standard chemotherapy significantly delays disease progression and improves overall survival in patients with previously untreated metastatic nonsquamous non-small-cell lung cancer, KEYNOTE-189 data show.

A selective inhibitor of the receptor tyrosine kinase RET could benefit patients with tumors harboring alterations in the oncogene, suggest early results presented at the American Association for Cancer Research Annual Meeting 2018.

CheckMate-227 shows that treatment with nivolumab plus ipilimumab significantly improves progression-free survival compared with chemotherapy in patients with advanced non-small-cell lung cancer and a high tumor mutational burden.